Linked Life Data

18473964

Source:http://linkedlifedata.com/resource/pubmed/id/18473964

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-5-13
pubmed:abstractText
The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodine-refractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1574-8871
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
133-41
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Iodine-refractory thyroid carcinoma.
pubmed:affiliation
Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA.
pubmed:publicationType
Journal Article, Review